Geosciences Consultants

Most of the clinical and economic burden of Respiratory Syncytial Virus (RSV) in pediatric populations is concentrated among infants aged < 1 year. This study aimed to estimate the recent incidence, healthcare costs and rehospitalization risk associated with RSV-related hospitalizations in infants < 1 year of age in France. The study analyzed the French National Hospital Database (PMSI) between January 1, 2016 and December 31, 2023. Outside of the classically defined epidemic season (October–March), RSV-related hospitalizations in infants were identified based on RSV-specific diagnosis codes and by both specific and non-specific RSV diagnosis codes during the epidemic season. Analyses were stratified by calendar months, by age in months and weeks for infants under 2 months. Lengths of stays (LOS), intensive care units (ICU) admissions, costs and rehospitalization rates were described. Rehospitalization rate was assessed using the Kaplan-Meier estimator. A total of 354,837 RSV-related hospitalizations were identified, representing an average of 44,355 per year, and a rate of 4.9 hospitalizations per 1,000 births. Overall, 76.4% occurred between November and February (epidemic peak), and 21.1% in September-October and March-April (transition months). ICU admission was observed in 27.2% of hospitalizations. The median (Q1–Q3) hospital and ICU LOS were 3.0 days (1.0–5.0) and 3.0 days (2.0–5.0), respectively. The mean (SD) hospital cost was €3,110 (€4,694), for an annual cumulative cost of €137.9 million. Younger infants had longer and costlier stays, with greater need for ICU. Infants younger than 3 months accounted for 46.5% of the hospitalizations, 58.5% of ICU stays and 54.9% of cumulative LOS. RSV-associated rehospitalization rates [95%CI] were 10.1% [10.0%–10.3%] and 11.7% [11.5%–11.9%] at three and 12 months, respectively. RSV infections are estimated to cause > 44,000 hospitalizations annually in infants in France, representing a total cost exceeding €130 million, annually. This study highlighted the impact of transitional months in RSV circulation. It also emphasized that the youngest patients (< 3 months) represent nearly 50% of the economic burden. To reduce RSV disease burden, it is essential to protect infants against RSV both inside and outside the classically defined epidemic season, especially in the first months of life. Not applicable.

RationaleNd:YAG (neodymium:yttrium-aluminum-garnet) capsulotomy (Nd:YAG-caps) is the gold standard for the treatment of PCO (Posterior Capsule Opacification). There is a lack of real-world data about Nd:YAG-caps use.PurposeThis study’s objectives were to estimate Nd:YAG-caps incidence in France, to describe the patient characteristics, and to analyze the time between surgeries and capsulotomies. Setting: The study was based on data extracted from the EGB database, a 1/97th sample representative of the French population. Design: observational, retrospective, cohort study using national claims data.MethodsFrench adult patients who underwent Nd:YAG-caps between 2014 and 2017 were selected. Main outcomes were the number of patients and procedures performed and the risk factors associated with early Nd:YAG-caps. Results: During the study period, Nd:YAG-caps were performed in 8,425 patients accounting for 10,774 procedures. The extrapolation to the French population led to estimate that 253.103 patients had Nd:YAG-caps, representing 312.103 procedures in 2017. The mean age at Nd:YAG-caps was 75.1 (± 10.2) years. About 36% of patients presented at least one ocular comorbidity. Nd:YAG-caps was performed within 2 years after surgery in 33.0% of patients and within one year in 9.8% of patients. Patients with Nd:YAG-caps within the first year (OR CI95 0.721 [0.673–0.772]) or in the first two years (OR CI95 0.721 [0.673–0.772]) were younger than patients with later Nd:YAG-caps and had a more frequent history of treated ocular diseases (OR 1.516 and 1.178, respectively).ConclusionsThis study brought new real-world and large-scale data regarding Nd:YAG-caps use and gave an updated insight into the patients’ characteristics.